Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
about
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyTargeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody.In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patientsNatural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancerNatural killer cell mediated cytotoxic responses in the Tasmanian devilTGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cellsA phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.Targeting the function of the HER2 oncogene in human cancer therapeutics.IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.New aspects of natural-killer-cell surveillance and therapy of cancer.New directions in natural killer cell-based immunotherapy of human cancer.T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survivalSynergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.Genkwadaphnin induces IFN-γ via PKD1/NF-κB/STAT1 dependent pathway in NK-92 cells.Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancerAnalysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.β-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruptionMolecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerNatural killer cells: from bench to cancer therapy.Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells.Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.Expression of MIF and c-erbB-2 in endometrial cancer.Engineering antigen-specific primary human NK cells against HER-2 positive carcinomasFolate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.Vaccine-induced antibody responses in patients with carcinoma.Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.Emerging immunotherapy strategies in breast cancer.Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions.Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilarGamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma
P2860
Q26797345-53FD1988-81F6-4758-83BC-D98BAEB5B655Q30497901-029AE5CE-97A7-42A0-B55B-72B6515434DDQ33620124-14627C8E-9933-457A-A11B-781A884203B1Q33621891-F2774F7A-5E5F-42E5-8C40-E133D11FD41BQ33672480-1A000E1B-D54B-417A-9D10-05948C995E22Q33715830-6A6B3B77-C9E7-4018-8979-67518919CA46Q34034657-9EB81A12-34F5-432B-AF3C-C22EF1B25953Q34076526-A9FC31C0-0796-42BC-AB86-4D3104187205Q34376968-9D942AB4-866B-4272-890A-6D5EDF910E38Q34382125-10963459-FA36-47D7-AB84-94C6B9CFA4DFQ34672927-AF959F28-3F28-4ED7-8011-135E9C4ED565Q34766486-A0A8E576-3923-4DA6-8DD8-40EFA216B3FFQ34798580-FD913BA8-33B9-49F9-A6FC-A039F5EFB936Q34988265-2D7EAD19-2EE8-42F6-9B41-FE8EDC88B6C4Q35093608-C7148468-F0FD-4EE2-8B84-7AE73A4BC8BAQ35212682-42BD1094-7AC0-4500-B639-73EC3CFC5A65Q35437978-4135B635-D909-4103-9657-C7B5E86F4D96Q35527121-E8D3C696-3350-4178-9BAA-8FFD52825F8CQ36060352-1B654F01-D8F4-4B68-AA87-6B2C17C61FBEQ36139709-D75C6EC7-73A1-4A1F-B29C-3A0A9E56617CQ36309917-AF547DFD-7AC1-4ADC-B552-B7718C28FB59Q36440214-0EE59381-0CCE-492F-8D30-41B868233F94Q36600223-4CD88B9C-F6AF-43FB-88CB-03EAAED8E0F7Q36613598-0AD16B3E-95E6-4F3E-9C1F-B8A29E860118Q36698273-315BDFEA-7F4C-4F6B-A910-FE144126BF1CQ36702442-E98D0D79-3E41-49BA-8414-2B9B5417472FQ36817369-2220A5CC-50FB-4F9A-9DB7-3679C3D79E2EQ36970863-FBDFC690-E5A1-4993-AA3A-236955DDA910Q37053016-45862F88-73FA-4037-B6ED-D021829B7087Q37725978-61E1C0B5-AC96-4B25-96CC-13B1EF650089Q37762272-D3329E0D-9B20-4CEA-954F-1A100C6E30F1Q37866150-7D6B5C12-F9DA-49EB-A01B-A6F0A675B698Q38184650-C11FF146-F3FC-4230-ADC3-9B8E9A06486CQ38469030-45863EBB-5B74-4A1F-80FC-A350A69BE9DAQ38542034-2D95022E-A966-40CA-A4D4-3F172CF4B106Q38671546-4754AC2B-703D-4A1C-AE7D-B3C42BB4B9EDQ38896842-F792F1FA-E9DC-4181-B681-F839EB8357E6Q38906179-DBA0306E-F149-4FEC-AD0E-2C5357DEDB73Q39212216-A1649240-6C24-47AD-BE10-1BA509C45CDEQ39290976-AF26A15D-89EC-4422-84C8-FF213D046D2D
P2860
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Interleukin-2 enhances the nat ...... -positive breast cancer cells.
@en
Interleukin-2 enhances the nat ...... -positive breast cancer cells.
@nl
type
label
Interleukin-2 enhances the nat ...... -positive breast cancer cells.
@en
Interleukin-2 enhances the nat ...... -positive breast cancer cells.
@nl
prefLabel
Interleukin-2 enhances the nat ...... -positive breast cancer cells.
@en
Interleukin-2 enhances the nat ...... -positive breast cancer cells.
@nl
P2093
P2860
P1476
Interleukin-2 enhances the nat ...... -positive breast cancer cells.
@en
P2093
J Dierksheide
M A Caligiuri
M J Lindemann
N J Meropol
W E Carson
P2860
P304
P356
10.1002/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J
P407
P577
2001-10-01T00:00:00Z